机译:开放标签,随机,多中心,平行研究比较了2型糖尿病患者中Glucerna和Fresubin的血糖反应和安全性
Shanghai Clinical Center for Endocrine and Metabolic Diseases Shanghai Institute of Endocrinology and Metabolism Division of Endocrine and Metabolic Diseases in E-Institute of Shanghai Universities Ruijin Hospital Shanghai Jiaotong University Medical School Ruijin 2nd Road 197 Shanghai 200025 P.R. China;
Shanghai Clinical Center for Endocrine and Metabolic Diseases Shanghai Institute of Endocrinology and Metabolism Division of Endocrine and Metabolic Diseases in E-Institute of Shanghai Universities Ruijin Hospital Shanghai Jiaotong University Medical School Ruijin 2nd Road 197 Shanghai 200025 P.R. China;
Department of Endocrinology Chang Hai Hospital Shanghai 200433 P.R. China;
Department of Endocrinology Chang Zheng Hospital 200003 Shanghai P.R. China;
Department of Endocrinology You Yi Hospital Beijing 100050 P.R. China;
Department of Endocrinology General Hospital Tianjin 300052 P.R. China;
Department of Endocrinology Chang Hai Hospital Shanghai 200433 P.R. China;
Department of Endocrinology Chang Hai Hospital Shanghai 200433 P.R. China;
Department of Endocrinology Chang Zheng Hospital 200003 Shanghai P.R. China;
Department of Endocrinology Chang Zheng Hospital 200003 Shanghai P.R. China;
Department of Endocrinology You Yi Hospital Beijing 100050 P.R. China;
Department of Endocrinology You Yi Hospital Beijing 100050 P.R. China;
Department of Endocrinology General Hospital Tianjin 300052 P.R. China;
Abbott Abbott Park IL USA;
Shanghai Clinical Center for Endocrine and Metabolic Diseases Shanghai Institute of Endocrinology and Metabolism Division of Endocrine and Metabolic Diseases in E-Institute of Shanghai Universities Ruijin Hospital Shanghai Jiaotong University Medical School Ruijin 2nd Road 197 Shanghai 200025 P.R. China;
Glucerna; Fresubin; Type 2 diabetes mellitus; Glucose response test;
机译:开放标签,随机,多中心,平行研究,比较了2型糖尿病受试者中Glucerna和Fresubin的血糖反应和安全性。
机译:研究方案的前瞻性,多中心,随机,开放标签,并联群临床试验比较无针胰岛素注射器的功效和安全性和传统的胰岛素笔控制中国2型糖尿病患者血糖浓度( 免费学习)
机译:在口服抗糖尿病药物治疗的日本2型糖尿病患者中,艾塞那肽每周一次与胰岛素每日一次的疗效和安全性比较:一项为期26周,随机,开放标签,平行分组,多中心,非劣效性研究的结果
机译:随机,多中心,开放标签,平行小组研究对SMARTCARE-糖尿病管理系统对糖尿病患者的影响
机译:儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验:对血糖控制的影响。
机译:利拉鲁肽与西格列汀在一项为期24周多中心开放标签随机平行组的日本2型糖尿病患者对磺脲类药物和/或一种或两种其他口服抗糖尿病药物反应不佳的研究中(JDDM 33)
机译:PDM011011胶囊的功效和安全性与患有2型糖尿病的Metformin相比:开放标签,随机,主动控制,多中心,III期研究